Perspective Zika vaccine trials

Promising data for candidate vaccines against Zika virus infection reported by Abbink et al. (1) on page 1129 of this issue raise hopes that one or more Zika virus vaccines may soon be ready for efficacy trials. Recent years have seen a barrage of emerging infectious diseases, including those caused by new pathogens such as Middle East respiratory syndrome (MERS) coronavirus, and those that are newly salient because of increased geographic spread, higher incidence, or genetic change, such as influenza A(H1N1)pdm09, Ebola virus, and Zika virus. Developing effective vaccines is a central goal for such pathogens. Authors: Marc Lipsitch, Benjamin J. Cowling
Source: ScienceNOW - Category: Science Authors: Tags: Infectious Disease Source Type: news

Related Links:

AbstractThe role of viral load in the outcome of patients requiring hospital admission due to influenza is not well established. We aim to assess if there is an association between the viral load and the outcome in hospitalized patients with a confirmed influenza virus infection. A retrospective observational study including all adult patients who were hospitalized in our center with a confirmed influenza virus infection from January to May 2016. Viral load was measured by real-time reverse-transcriptase –polymerase chain reaction (rRT-PCR) cycle threshold (Ct) value on upper respiratory tract samples. Its value was ...
Source: European Journal of Clinical Microbiology and Infectious Diseases - Category: Microbiology Source Type: research
AbstractDiagnosing a patient with Zika infection is not always straightforward. Here, we aim to describe our data collected from December 2015 to December 2017 and discuss the implemented algorithm and diagnostic challenges we encountered. At the National Reference Center for Arboviruses at the Institute of Tropical Medicine, Antwerp, Belgium (ITM), a commercial Zika virus (ZIKV) enzyme-linked immunosorbent assay (ELISA) detecting immunoglobulin (Ig) M and IgG, a commercial ZIKV immunofluorescence assay (IFA) detecting IgM, and an in-house Zika virus neutralization test (VNT) were implemented. For molecular detection of ZI...
Source: European Journal of Clinical Microbiology and Infectious Diseases - Category: Microbiology Source Type: research
In this study, we used silkworm pupae to develop a safer vaccine for Alzheimer’s disease (AD) patients. Aβ15 peptide was fused with the cholera toxin B subunit (CTB) and expressed in silkworm pupae. Then, we tested an oral vaccine with the peptide expressed by silkworm pupae in a transgenic mouse model of AD. The results show that anti-Aβ antibodies were induced, Aβ deposition in the brain decreased, the content of malondialdehyde was lower than in the other group, and memory and cognition of the mice improved. These results suggest that the high-nutrient CTB-Aβ15 silkworm pupa vaccine has ...
Source: Journal of Biotechnology - Category: Biotechnology Source Type: research
Publication date: Available online 18 March 2019Source: BiologicalsAuthor(s): Shuyun Qin, Dmitriy Volokhov, Elvira Rodionova, Christoph Wirblich, Matthias J. Schnell, Vladimir Chizhikov, Alena DabrazhynetskayaAbstractThe Rapid Fluorescent Focus Inhibition Test (RFFIT) is a standard assay used to detect and assess the titers of rabies virus neutralizing antibodies (RVNA) in blood sera. To simplify the multistep RFFIT procedure by eliminating the immunostaining step, we generated a new recombinant RV expressing a green fluorescent protein (rRV-GFP) and assess its suitability for quantifying RVNA. We rescued the rRV-GFP virus...
Source: Biologicals - Category: Biology Source Type: research
Conclusion: LPR may be a risk factor for JORRP, contributing to its development by activating or reactivating a latent HPV infection. Results are in accordance with those from our previous study in adults. PMID: 30881982 [PubMed - in process]
Source: Biomed Res - Category: Research Authors: Tags: Biomed Res Int Source Type: research
Condition:   Vaccination; Infection Intervention:   Biological: Infanrix hexa or Vaxelis Sponsors:   University of Oxford;   MCM Vaccines B.V. Not yet recruiting
Source: ClinicalTrials.gov - Category: Research Source Type: clinical trials
Condition:   Influenza Interventions:   Biological: MVA-NP+M1;   Drug: Saline Sponsors:   Vaccitech Limited;   Clinical Network Services (CNS) Pty Ltd Not yet recruiting
Source: ClinicalTrials.gov - Category: Research Source Type: clinical trials
Conditions:   Lung Atypical Carcinoid Tumor;   Lung Typical Carcinoid Tumor;   Metastatic Digestive System Neuroendocrine Neoplasm;   Metastatic Lung Neuroendocrine Neoplasm;   Metastatic Pancreatic Neuroendocrine Tumor;   Survivin Positive Interventions:   Biological: Incomplete Freund's Adjuvant;   Drug: Octreotide Acetate;   Biological: Sargramostim;   Biological: SVN53-67/M57-KLH Peptide Vaccine Sponsors:   Roswell Park Cancer Institute; &nbs...
Source: ClinicalTrials.gov - Category: Research Source Type: clinical trials
Conditions:   Venezuelan Equine Encephalitis;   Western Equine Encephalitis;   Eastern Equine Encephalitis;   Alphavirus Infections Interventions:   Biological: VRC-WEVVLP073-00-VP;   Other: VRC-GENMIX083-AL-VP Sponsors:   National Institute of Allergy and Infectious Diseases (NIAID);   The EMMES Corporation;   Leidos Biomedical Research, Inc.;   Battelle Not yet recruiting
Source: ClinicalTrials.gov - Category: Research Source Type: clinical trials
Jerome Kunkel, an 18-year-old senior and basketball captain at a Catholic school in Walton, objects to vaccines because he believes they 'contain aborted fetal cells'.
Source: the Mail online | Health - Category: Consumer Health News Source Type: news
More News: Coronavirus | Ebola | Ebola Vaccine | Genetics | H1N1 | Infectious Diseases | Influenza | Influenza Vaccine | MERS | Middle East Health | Respiratory Medicine | Science | Swine Flu (H1N1) Vaccine | Vaccines | Zika Virus